Table 3.
Cumulative incidence and Cox regression analysis of type 2 diabetes over time in participants with and without breast cancer
| Variable | Incidence/1,000 person‐years | Crude HR (95% CI) | Adjusted HR† (95% CI) | |
|---|---|---|---|---|
| Breast cancer | No breast cancer | Breast cancer vs no breast cancer | Breast cancer vs no breast cancer | |
| Year 1 | 92.6 | 53.6 | 1.85 (1.53–2.23)*** | 1.70 (1.40–2.05)*** |
| Year 2 | 67.3 | 37.0 | 1.55 (1.31–1.83)*** | 1.44 (1.22–1.71)*** |
| Year 3 | 57.5 | 31.8 | 1.44 (1.24–1.68)*** | 1.35 (1.16–1.57)** |
| Year 4 | 52.9 | 28.7 | 1.45 (1.26–1.67)*** | 1.36 (1.18–1.57)*** |
| Year 5 | 49.5 | 27.2 | 1.42 (1.24–1.63)*** | 1.34 (1.17–1.54)*** |
| Year 6 | 47.1 | 26.5 | 1.39 (1.22–1.59)*** | 1.32 (1.15–1.50)*** |
| Year 7 | 45.4 | 25.6 | 1.38 (1.22–1.57)*** | 1.31 (1.15–1.49)*** |
| Year 8 | 44.4 | 25.2 | 1.38 (1.22–1.56)*** | 1.31 (1.16–1.49)*** |
| Year 9 | 43.2 | 24.8 | 1.37 (1.21–1.54)*** | 1.30 (1.15–1.47)*** |
| Year 10 | 41.9 | 24.5 | 1.34 (1.19–1.51)*** | 1.27 (1.13–1.44)*** |
| Year 11 | 41.4 | 24.3 | 1.34 (1.19–1.50)*** | 1.27 (1.13–1.43)*** |
| Year 12 | 40.9 | 24.2 | 1.33 (1.18–1.49)*** | 1.27 (1.12–1.42)** |
| Year 13 | 40.5 | 24.0 | 1.32 (1.18–1.49)*** | 1.26 (1.12–1.42)** |
| Year 14 | 40.1 | 24.0 | 1.31 (1.17–1.47)*** | 1.25 (1.11–1.40)** |
| Year 15 | 39.9 | 24.0 | 1.31 (1.16–1.47)*** | 1.24 (1.11–1.40)** |
Censored cases were defined as the follows: (i) recurrence of breast cancer (surgery/chemotherapy/hormone therapy for breast cancer at 1 year after the index date); (ii) the presence of new cancer or metastasis; (iii) death; and (iv) end of observation (follow up for 1–10 years after the index date). †Model adjusted for age, income, urbanization, Charlson Comorbidity Index, and history of hyperlipidemia, hypertension, cardiovascular disease and cerebrovascular disease. CI, confidence interval; HR, hazard ratio.**P < 0.05; ***P < 0.01